SALT LAKE CITY, Utah, March 5, 2015 – Myriad RBM, a wholly-owned subsidiary of Myriad Genetics, Inc., (NASDAQ: MYGN) today announced the launch of immunoassay services based on the ultrasensitive Simoa™ (single molecule array) platform developed by Quanterix. The Simoa platform enables the accurate measurement of protein biomarkers that were previously difficult or even impossible to detect in blood samples.
“The Simoa platform is an exciting new tool that is 100 to 1,000 times more sensitive than conventional tests for blood-based protein biomarkers and will open up new avenues of clinical research,” said Ralph McDade, president of Myriad RBM. “We believe Simoa will significantly accelerate biomedical discoveries by providing researchers with valuable insights into both the underlying mechanisms of disease and the safety and efficacy of pharmaceuticals.”
Initially, Myriad RBM will offer Simoa assay services for the study of inflammatory and autoimmune diseases. The Company has manufactured and validated Simoa-based quantitative immunoassays for interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) that are available from its CLIA-certified laboratory in Austin, Texas. Each assay includes carefully designed calibrators and controls to provide multiple measurements of quality, precision and accuracy. Myriad RBM plans to add more Simoa-based immunoassays throughout the year.
The Simoa platform adds to Myriad RBM’s long-standing track record of scientific excellence and commitment to providing high quality immunoassay research services. For more than 13 years, the Company has been a leading provider of multiplex immunoassay testing services to the biopharmaceutical industry and has earned a reputation for quality, a broad menu of assays and exceptional customer service.
“Understanding the incredible role of quantifying ultra-low concentrations of protein biomarkers in human blood samples and their linkage to the complex mechanisms of a disease has the potential to revolutionize the field of medicine as we know it,” said Kevin Hrusovsky, executive chairman of Quanterix. “We are very pleased to be collaborating with Myriad RBM and to be working together to provide access to these important new developments in healthcare.”
The Quanterix Simoa technology has been available to researchers since early 2014 following the successful validation of the tool’s ability to measure multiple proteins simultaneously at the single molecule level using its novel technology. The unprecedented sensitivity of Simoa is the result of digital counting of chemical binding events that occur based on standard immunoassay chemistry.
The Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Simoa is a trademark of Quanterix.
About Myriad RBM
Myriad RBM is a wholly owned subsidiary of Myriad Genetics, Inc. Its biomarker discovery platform provides clinical researchers and healthcare providers with reproducible, quantitative, multiplexed data for hundreds of proteins to advance drug development and patient care. The Company’s proprietary Multi Analyte Profiling (MAP) technology offers preclinical and clinical researchers with broad, cost-effective analyses of multiple proteins from a single, small sample volume. MAP technology also supports Myriad RBM’s drive to develop companion diagnostics in areas of unmet medical need such as neuropsychiatry, nephrology and immunology. More information about Myriad RBM can be found at www.myriadrbm.com.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients’ lives through the discovery and commercialization of transformative tests to assess a person’s risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad is focused on strategic directives to grow our markets, introduce new products, including companion diagnostics, as well as to expand internationally. For more information on how Myriad is making a difference, please visit the Company’s website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan Lung Cancer, BRACAnalysis CDx, Tumor BRACAnalysis CDx, HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G